Sigma Planning Corp’s Atossa Therapeutics ATOS Stock Holding History

Sigma Planning Corp’s Portfolio ATOS Stock Details ATOS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-1,600	Closed	-$14.2K	–	1318
2025 Q4	$14.2K	Hold	1,600	–	–	﹤0.01%	1290
2025 Q3	$20.8K	Buy	+1,600	New	+$19.8K	﹤0.01%	1287

Other funds holding ATOS

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Sigma Planning Corp's ATOS Position: Q1 2026 in Review

Sigma Planning Corp sold out of Atossa Therapeutics (ATOS) in Q1 2026, closing a stake of 1,600 shares — an estimated $14.2K sold.

Sigma Planning Corp first reported a position in ATOS in Q3 2025 and held it in 2 quarters. The position peaked at $20.8K in Q3 2025. 33 funds tracked by Wall St. Rank hold ATOS as of Q1 2026.

Sigma Planning Corp reported no remaining Atossa Therapeutics position as of Q1 2026 after selling out during the quarter.
Sigma Planning Corp sold 1,600 Atossa Therapeutics shares in Q1 2026, an estimated $14.2K.
Sigma Planning Corp first reported a position in Atossa Therapeutics in Q3 2025 and held it in 2 quarters.
Sigma Planning Corp's Atossa Therapeutics position peaked at $20.8K in Q3 2025.
33 funds tracked by Wall St. Rank held Atossa Therapeutics as of Q1 2026.

Based on Sigma Planning Corp's 13F filing for Q1 2026, filed 4 May 2026.